Skip to main content
    V

    Vera Therapeutics Inc (VERA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.97
    -1.13 (-4.02%)

    Market Cap: $2.03B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vera Therapeutics Inc (VERA) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Vera Therapeutics (VERA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Vera Therapeutics reported EPS of -$1.30, above the -$1.72 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    35%(8/23)
    Avg Surprise
    -31.90%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.40
    Range-$2.12 - -$1.17
    13 analysts
    Revenue Consensus
    $19.09M
    Range$10.78M - $33.81M
    12 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.24
    Range-$1.39 - -$1.06
    4 analysts
    EPS Revisions
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.33+7.4%
    60d ago-$1.30+5.1%
    30d ago-$1.29+4.3%
    7d ago-$1.33+7.1%
    Current-$1.24
    Revenue Consensus
    $39.93M
    Range$33.20M - $46.93M
    8 analysts

    Next Report

    VERA has an expected report date of Feb 24, 2027.

    VERA Earnings Call

    The latest VERA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, VERA beat 8 and missed 15. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 530.41% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$1.30-$1.72-$1.80 - -$1.39+24.42%BeatN/A81 up, 0 downNov 5, 2026
    Jun 30, 2026-$1.52-$1.60-$1.73 - -$1.38+5.00%BeatN/A71 up, 0 downAug 10, 2026
    Mar 31, 2026-$1.69-$1.37-$1.66 - -$1.20-23.36%MissN/A51 up, 3 downMay 7, 2026
    Dec 31, 2025-$1.39-$1.34-$1.62 - -$1.11-3.73%MissN/A82 up, 0 downFeb 26, 2026
    Sep 30, 2025-$1.26-$1.20-$1.30 - -$0.93-5.00%MissN/A70 up, 0 downNov 5, 2025
    Jun 30, 2025-$1.20-$0.62-$0.90 - $0.69-93.55%MissN/A7N/AAug 5, 2025
    Mar 31, 2025-$0.81-$0.78-$0.81 - -$0.76-3.85%MissN/A41 up, 0 downMay 6, 2025
    Dec 31, 2024-$0.72-$0.81-$0.90 - -$0.62+11.11%BeatN/A32 up, 1 downFeb 26, 2025
    Sep 30, 2024-$0.85-$0.62-$0.81 - -$0.58-37.10%MissN/A91 up, 0 downNov 7, 2024
    Jun 30, 2024-$0.62-$0.54-$0.65 - -$0.48-14.81%MissN/A80 up, 0 downAug 8, 2024
    Mar 31, 2024-$0.56-$0.53-$0.60 - -$0.46-5.66%MissN/A60 up, 0 downMay 9, 2024
    Dec 31, 2023-$0.58-$0.51-$0.58 - -$0.42-13.73%MissN/A90 up, 0 downMar 20, 2024
    Sep 30, 2023-$0.45-$0.54-$0.70 - -$0.50+16.67%BeatN/A61 up, 0 downNov 9, 2023
    Jun 30, 2023-$0.46-$0.74-$0.82 - -$0.42+37.84%BeatN/A60 up, 0 downAug 10, 2023
    Mar 31, 2023-$0.80-$0.45-$0.80 - -$0.45-77.78%MissN/A60 up, 2 downMay 11, 2023
    Dec 31, 2022-$1.18-$0.90-$1.02 - -$0.68-31.11%MissN/A60 up, 0 downMar 28, 2023
    Sep 30, 2022-$0.91-$0.90-$0.90 - -$0.64-1.11%MissN/A60 up, 0 downNov 9, 2022
    Jun 30, 2022-$0.55-$0.78N/A+29.49%BeatN/AN/A0 up, 0 downAug 10, 2022
    Mar 31, 2022-$0.71-$0.64-$0.73 - -$0.62-10.94%MissN/A50 up, 0 downMay 16, 2022
    Dec 31, 2021-$0.79-$0.46-$0.49 - -$0.44-71.74%MissN/A20 up, 0 downMar 24, 2022
    Sep 30, 2021-$0.36-$0.59-$0.75 - -$0.44+38.98%BeatN/A21 up, 0 downNov 10, 2021
    Jun 30, 2021-$0.33-$0.45-$0.45 - -$0.33+26.67%BeatN/A2N/AAug 16, 2021
    Mar 31, 2021-$12.23-$1.94N/A-530.41%MissN/AN/AN/AApr 23, 2021
    Dec 31, 2020-$2.02N/AN/AN/AN/AN/AN/AN/ADec 31, 2020
    Sep 30, 2020-$0.21N/AN/AN/AN/AN/AN/AN/ASep 30, 2020
    Jun 30, 2020-$0.17N/AN/AN/AN/AN/AN/AN/AJun 30, 2020
    Mar 31, 2020-$0.12N/AN/AN/AN/AN/AN/AN/AJun 29, 2020
    Last 27 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$4.66, after -$2.75 the year before. It was -$2.51 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$4.66N/A
    Dec 31, 2024-$2.75N/A
    Dec 31, 2023-$2.29N/A
    Dec 31, 2022-$3.35N/A
    Dec 31, 2021-$13.71N/A
    Dec 31, 2020-$2.51N/A

    Earnings Calls

    The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,68716

    2026Q3 Earnings Call

    Opening remarks

    Joshua Qin Vice President of Corporate Finance and Investor Relations Thank you, operator, and thank you, everyone, for joining us. Earlier today, we issued a press release announcing our business highlights and financial results for the quarter ended September 30, 2026. A copy of the press release is available in the Investors and Media section of our website at ir.veratx.com. Before we begin, I would like to remind everyone that we will be making various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The company cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. We encourage everyone to review the company's filings with the SEC, including, without limitation, the company's most recent Form 10-K and Form 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. In addition, today's discussion includes results from ongoing clinical trials of atacicept in investigational uses that have not been approved by the FDA or any other regulatory authority. The full prescribing information for TRUTAKNA, including important safety information, is available on our website. Furthermore, the content of this webcast contains time-sensitive information that is accurate only as of the date of the live broadcast, November 5, 2026. Vera undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this broadcast. This webcast is being recorded, and an archive will be available on our website for 30 days. With that, I will turn the call over to Dr. Marshall Fordyce, Founder and Chief Executive Officer. Marshall?

    Marshall Fordyce Founder and Chief Executive Officer Thank you, Josh, and welcome, everyone. Joining me today are Dr. Robert Brenner, our Chief Medical Officer; Matt Skelton, our Chief Commercial Officer; and Sean Grant, our Chief Financial Officer. The third quarter marked a major turning point for Vera. Following accelerated approval from the FDA in July, we launched TRUTAKNA, the first therapy approved in the U.S. that targets both BAFF and APRIL to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Since the accelerated approval of TRUTAKNA on July 7, we have received approximately 700 patient start forms to date. This early momentum exemplifies our longstanding confidence in TRUTAKNA's potential to become a foundational therapy for IgA nephropathy, and it represents an important first step in delivering on our commitment to people living with this disease. We're sharing this figure today because we believe it's the best measure of demand at this early stage of launch.

    Frequently Asked Questions About VERA

    When is Vera Therapeutics's next earnings date?

    Vera Therapeutics's next earnings report is expected for Feb 24, 2027.

    Did VERA beat earnings estimates last quarter?

    Yes. Vera Therapeutics reported EPS of -$1.30 for the quarter ended Sep 30, 2026, above the -$1.72 estimate, a 24.42% surprise.

    What EPS do analysts expect from VERA next quarter?

    The consensus EPS estimate for Vera Therapeutics for the quarter ending Dec 31, 2026 is -$1.40 from 13 analysts, with estimates from -$2.12 to -$1.17.

    How often does VERA beat earnings estimates?

    Vera Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -11.12%.